Literature DB >> 20500230

Breast cancer precursors revisited: molecular features and progression pathways.

Maria A Lopez-Garcia1, Felipe C Geyer, Magali Lacroix-Triki, Caterina Marchió, Jorge S Reis-Filho.   

Abstract

Increasingly more coherent data on the molecular characteristics of benign breast lesions and breast cancer precursors have led to the delineation of new multistep pathways of breast cancer progression through genotypic-phenotypic correlations. It has become apparent that oestrogen receptor (ER)-positive and -negative breast lesions are fundamentally distinct diseases. Within the ER-positive group, histological grade is strongly associated with the number and complexity of genetic abnormalities in breast cancer cells. Genomic analyses of high-grade ER-positive breast cancers have revealed that a substantial proportion of these tumours harbour the characteristic genetic aberrations found in low-grade ER-positive disease, suggesting that at least a subgroup of high-grade ER-positive breast cancers may originate from low-grade lesions. The ER-negative group is more complex and heterogeneous, comprising distinct molecular entities, including basal-like, HER2 and molecular apocrine lesions. Importantly, the type and pattern of genetic aberrations found in ER-negative cancers differ from those of ER-positive disease. Here, we review the available molecular data on breast cancer risk indicator and precursor lesions, the putative mechanisms of progression from in situ to invasive disease, and propose a revised model of breast cancer evolution based on the molecular characteristics of distinct subtypes of in situ and invasive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500230     DOI: 10.1111/j.1365-2559.2010.03568.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  104 in total

Review 1.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

2.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

3.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

Review 4.  Breast cancer metastasis through the lympho-vascular system.

Authors:  S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera
Journal:  Clin Exp Metastasis       Date:  2018-05-23       Impact factor: 5.150

Review 5.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

6.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

7.  RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.

Authors:  Chaido Sirinian; Anastasios D Papanastasiou; Michail Schizas; Magda Spella; Georgios T Stathopoulos; Maria Repanti; Ioannis K Zarkadis; Tari A King; Haralabos P Kalofonos
Journal:  Oncogene       Date:  2018-05-29       Impact factor: 9.867

Review 8.  Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

9.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

10.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.